| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018，68(1): 7-30.
|
| [2] |
Kimbung S, Lettiero B, Feldt M, et al. High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer[J]. Oncotarget, 2016, 7(37): 59 640-59 651.
|
| [3] |
Stryjkowska-Góra A, Karczmarek-Borowska B, Góra T, et al. Statins and cancers[J]. Contemp Oncol (Pozn), 2015, 19(3): 167-175.
|
| [4] |
Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins[J]. Oncogene, 2012, 31(48): 4967-4978.
|
| [5] |
Lin Z, Zhang Z, Jiang X, et al. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells[J]. Oncotarget, 2017, 8(11): 17 833-17 848.
|
| [6] |
Alarcon Martinez T, Zeybek ND, Müftüoğlu S. Evaluation of the cytotoxic and autophagic effects of atorvastatin on MCF-7 breast cancer cells[J]. Balkan Med J, 2018, 35(3): 256-262.
|
| [7] |
Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial[J]. Breast Cancer Res Treat，2013，138(2): 499-508.
|
| [8] |
Liu H, Liang S L, Kumar S, et al. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression[J]. Cancer Chemother Pharmacol, 2009, 63(6): 997-1005.
|
| [9] |
Riganti C, Pinto H, Bolli E, et al. Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer[J]. Biochem Pharmacol, 2011, 82(9): 1079-1089.
|
| [10] |
Crescencio ME, Rodríguez E, Páez A, et al. Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells [J]. Int J Biomed Sci，2009，5(4): 411-420.
|
| [11] |
Altwairgi AK. Statins are potential anticancerous agents (review)[J]. Oncol Rep, 2015, 33(3): 1019-1039.
|
| [12] |
Beckwitt C, Wheeler SE, Clark AM, et al. Breast cancer dormancy, re-emergence, and treatment[J]. Cancer Res，2016，76(4 Suppl): P2-05-19.
|
| [13] |
Kanugula AK, Gollavilli PN, Vasamsetti SB, et al. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms[J]. FEBS J, 2014, 281(16): 3719-3738.
|
| [14] |
Kotamraju S, Willams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways[J]. Cancer Res, 2007, 67(15): 7386-7394.
|
| [15] |
沈园园，杜瀛瀛，袁媛，等. 辛伐他汀对人乳腺癌细胞MCF-7的生长抑制作用及机制研究[J]. 临床肿瘤学杂志，2015，20(4): 312-316.
|
| [16] |
朱宗平，赵小平，赵丽，等. 辛伐他汀和NONO对乳腺癌细胞增殖的影响[J]. 肿瘤，2015, 35(7): 741-750.
|
| [17] |
Yang T, Yao H, He G，et al.Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis[J]．J Cancer，2016，7(2): 192-199.
|
| [18] |
Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells [J]. J Cell Mol Med, 2013, 17(1): 30-54.
|
| [19] |
Agnihotri N, Kumar S, Mehta K, et al. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer[J]. Breast Cancer Res, 2013, 15(1): 202.
|
| [20] |
Beckwitt CH, Shiraha K, Wells A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling[J]. PLoS One，2018，13(5): e0197422.
|
| [21] |
Kusama T, Mukai M, Tatsuta M, et al. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho[J]. Int Jf Oncol, 2006, 29(1): 217-223.
|
| [22] |
Fritz G, Brachetti C, Bahlmann F, et al. Rho GTPases in human breast tumors: expression and mutation analyses and correlation with clinical parameters[J]. Br J Cancer, 2002, 87(6): 635-644.
|
| [23] |
Vintonenko N, Jais JP, Kassis N, et al. Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model[J]. Mol Pharmacol, 2012, 82(3): 521-528.
|
| [24] |
Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice[J]. Clin Cancer Res, 2000, 6(5): 2044-2052.
|
| [25] |
闫冰. 辛伐他汀联合紫杉醇靶向作用Hippo信号通路对乳腺癌干细胞的影响[D]. 大连：大连医科大学，2017.
|
| [26] |
Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study [J]. J Am Coll Cardiol，2012，60(23): 2384-2390.
|
| [27] |
Chavez-Mac Gregor M, Lei X, Litton JK, et al. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy[J]. Cancer Res 2013，73(24 Suppl): P3-12-06.
|
| [28] |
Brennan DJ, Laursen H, O’Connor DP, et al. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.[J]. Breast Cancer Res, 2011, 13(1): R12.
|
| [29] |
金伟，袁媛，汤继春，等. 他莫昔芬与辛伐他汀对人乳腺癌细胞MCF-7的协同效应及机制[J]. 安徽医科大学学报，2017，52(5): 677-681.
|
| [30] |
于金明，李建彬. 乳腺癌保乳术后放射治疗进展[J/CD]. 中华乳腺病杂志(电子版), 2007, 1(3): 3-9.
|
| [31] |
Miller AC, Kariko K, Myers CE, et al. Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation[J]. Int J Cancer, 1993, 53(2): 302-307.
|
| [32] |
Chan KK, Oza AM, Siu LL. The statins as anticancer agents[J]. Clin Cancer Res, 2003, 9(1): 10-19.
|
| [33] |
Sakellakis M, Akinosoglou K, Kostaki A, et al. Statins and risk of breast cancer recurrence[J]. Breast Cancer (Dove Med Press)，2016，8: 199-205.
|
| [34] |
Mansourian M, Haghjooy-Javanmard S, Eshraghi A, et al. Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies [J]. J Pharm Pharm Sci, 2016，19(1): 72-81.
|
| [35] |
Beckwitt CH, Clark AM, Ma B, et al. Statins attenuate outgrowth of breast cancer metastases[J]. Br J Cancer, 2018, 119(9): 1094-1105.
|
| [36] |
Schairer C, Freedman DM, Gadalla SM, et al. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a medicare population[J]. Breast Cancer Res Treat, 2018, 169(3): 607-614.
|
| [37] |
Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a danish nationwide prospective cohort study[J]. J Natl Cancer Inste, 2011, 103(19): 1461-1468.
|
| [38] |
Lettiero B, Inasu M, Kimbung S, et al. Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells[J]. Sci Rep, 2018, 8(1): 5462.
|
| [39] |
吴颖，王哲，孔静，等. 阿司匹林对HER-2阳性乳腺癌AU-565细胞增殖能力的影响[J/CD]. 中华乳腺病杂志(电子版), 2017，11(1): 19-23.
|